A n ageing population worldwide, coupled with a higher occurrence of eye conditions and diseases such as diabetic retinopathy, dry eye, glaucoma and age-related macular degeneration, has resulted in increased growth in the ophthalmic pharmaceutical market. Despite the obvious need for medicines, developing a new medicine is a risky business as well as costly in time and finances. It takes an average of 10 years for a new medicine to arrive to market (Phrma 2015) . The average cost to develop a medicine is estimated to be $2.5-5 billion with the overall probability of clinical success (drug approval) estimated to be 10-12% (Herper 2013; Millman 2014; Phrma 2015) .
A recent study examined ophthalmic pharmaceutical start-ups and found only 20% were able to licence their product after 4-15 years of existence (Stewart et al. 2013a) . Further when ophthalmic CEOs and Board of Director members were surveyed regarding the challenges facing device and pharmaceutical start-ups, they noted many financing and regulatory burdens made it difficult to bring new products to market (Stewart et al. 2013b ). Retinal thickness in lm (SD) in the macula of all individual layers and macular volume do not significantly differ between 15 patients with AD and 15 controls. * Independent sample t-test. AD = Alzheimer's disease, GCL = ganglion cell layer, INL = inner nuclear layer, IPL = inner plexiform layer, ONL = outer nuclear layer, OPL = outer plexiform layer, RNFL = retinal nerve fibre layer, RPE = retinal pigment epithelium. Inner ring = ETDRS regions 2-5, Outer ring = ETDRS regions 6-9.
A recent review of ophthalmic pharmaceutical and device companies with a new product in development showed a concentration of effort into relatively few indications (Sharpe et al. 2015) . The purpose of this study was to examine the outcomes of ophthalmic start-ups followed over 5 years to determine the success rate and factors associated with success.
The companies followed in this study came from an existing database of 190 ophthalmic companies with a new product in development (Sharpe et al. 2015) . The subanalysis included mid-sized companies (<200 employees) developing an ophthalmic pharmaceutical or device with information available online in English.
Baseline, follow-up and exit (licence/ sale of products, or sale of company) details were retrieved from company websites and/or general Internet searches. If exit details could not be found and there was no active website, the company was considered out of business.
Companies were classified as follows: 'unsuccessful' if they were no longer in business (could not be found online) or left ophthalmology; 'unchanged' if there was no successful financial exit, but still developing the product; or 'success' if the company was acquired, a product was acquired, the company went public or the company was purchased.
The study followed 63 ophthalmic companies of which, after 5 years of follow-up, there were three categories: unsuccessful (19%), unchanged (43%) and successful (38%). Data are summarized in Table 1 .
Statistically more unsuccessful companies (92%) were private versus public compared to unchanged (81%) and successful companies (42%; p = 0.001). Other measures did not show a statistical difference for success, including clinical indication, products per company, time in business, CEO retention, geographic location, device or pharmaceutical product, or development phase (p > 0.05).
The number of companies that apparently failed in ophthalmology over 5 years was only 19% while 38% had a successful licence or exit. This contrasts to a prior report of 20% success (Stewart et al. 2013a ). This success rate compares favourably with other therapeutic areas and their startup success rates, usually noted around 10-12% (rates for autoimmune, endocrine and infectious diseases) (Berkrot 2011) .
The one statistical difference found, companies who went public were more successful, is not a surprise as it was probably their success that led to the initial public offering. The other measures did not show a statistical difference in this study, but they differ, at least in 'time to exit', compared to a prior report showing a statistical difference at exit in most companies that were <5 years in business (Stewart et al. 2013a ). Our current finding may indicate the usefulness of extending development beyond 5 years.
Ophthalmic start-up companies have a reasonable chance of exiting their product, perhaps easier than other indications, although success factors are difficult to determine. Additional research is needed to understand more fully the reasons for success or failure of start-ups. Acta Ophthalmologica 2018
